Teza Capital Management’s United Therapeutics UTHR Stock Holding History

Teza Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,027	Closed	-$232K	–	765
2023 Q3	$232K	Sell	1,027 -123	-11%	-$28.3K	0.04%	492
2023 Q2	$254K	Buy	+1,150	New	+$255K	0.04%	447
2020 Q3	–	Sell	-12,379	Closed	-$1.5M	–	619
2020 Q2	$1.5M	Buy	+12,379	New	+$1.39M	0.33%	79
2018 Q3	–	Sell	-2,751	Closed	-$311K	–	559
2018 Q2	$311K	Sell	2,751 -2,655	-49%	-$292K	0.05%	417
2018 Q1	$607K	Buy	5,406 +2,206	+69%	+$280K	0.15%	257
2017 Q4	$473K	Buy	+3,200	New	+$407K	0.29%	152
2017 Q2	–	Sell	-2,759	Closed	-$374K	–	360
2017 Q1	$374K	Buy	+2,759	New	+$418K	0.11%	295

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Teza Capital Management's UTHR Position: Q4 2023 in Review

Teza Capital Management sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 1,027 shares — an estimated $232K sold.

Teza Capital Management first reported a position in UTHR in Q1 2017 and held it in 7 quarters. The position peaked at $1.5M in Q2 2020. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

Teza Capital Management reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
Teza Capital Management sold 1,027 United Therapeutics shares in Q4 2023, an estimated $232K.
Teza Capital Management first reported a position in United Therapeutics in Q1 2017 and held it in 7 quarters.
Teza Capital Management's United Therapeutics position peaked at $1.5M in Q2 2020.
535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Teza Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.